tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

OCGN Stock Latest News

Ocugen’s (OCGN) Stock Has Surged 195% on Promising Gene Therapy Treatment
Market NewsOcugen’s (OCGN) Stock Has Surged 195% on Promising Gene Therapy Treatment
10d ago
OCGN
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
PremiumPress Releases
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
11d ago
OCGN
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
PremiumPress Releases
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
15d ago
OCGN
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
PremiumPress Releases
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
17d ago
OCGN
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
PremiumPress Releases
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
23d ago
OCGN
Ocugen completes dosing in Phase 1/2 trial of Stargardt disease candidate
PremiumThe FlyOcugen completes dosing in Phase 1/2 trial of Stargardt disease candidate
23d ago
OCGN
Ocugen announces Health Canada sent “No Objection Letter” for OCU400 trial
Premium
The Fly
Ocugen announces Health Canada sent “No Objection Letter” for OCU400 trial
25d ago
OCGN
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Premium
Press Releases
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
25d ago
OCGN
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
1M ago
ENB
ANVS
Ocugen reports Q2 EPS (4c), consensus (5c)
PremiumThe Fly
Ocugen reports Q2 EPS (4c), consensus (5c)
1M ago
OCGN
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
PremiumPress Releases
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
1M ago
OCGN
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
PremiumPress Releases
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
2M ago
OCGN
Ocugen receives FDA approval for EAP for patients with retinitis pigmentosa
PremiumThe FlyOcugen receives FDA approval for EAP for patients with retinitis pigmentosa
2M ago
OCGN
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
Premium
Press Releases
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
2M ago
OCGN
Ocugen 30.4M share Spot Secondary priced at $1.15
Premium
The Fly
Ocugen 30.4M share Spot Secondary priced at $1.15
2M ago
OCGN
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
PremiumPress Releases
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
2M ago
OCGN
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
PremiumPress Releases
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
2M ago
OCGN
Ocugen announces common stock offering, no amount given
PremiumThe Fly
Ocugen announces common stock offering, no amount given
2M ago
OCGN
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
2M ago
UL
UP
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
PremiumPress ReleasesOcugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
2M ago
OCGN
Ocugen completes dosing in Phase 1/2 trial of OCU410 in geographic atrophy
Premium
The Fly
Ocugen completes dosing in Phase 1/2 trial of OCU410 in geographic atrophy
2M ago
OCGN
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
Premium
Press Releases
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
2M ago
OCGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >